摘要
Immunotherapy has made great progress in hepatocellular carcinoma (HCC), yet there is still a lack of biomarkers for predicting response to it. Cancer stem cells (CSCs) are the primary cause of the tumorigenesis, metastasis, and multi-drug resistance of HCC. This study aimed to propose a novel CSCs-related cluster of HCC to predict patients' response to immunotherapy. Based on RNA-seq datasets from The Cancer Genome Atlas (TCGA) and Progenitor Cell Biology Consortium (PCBC), one-class logistic regression (OCLR) algorithm was applied to compute the stemness index (mRNAsi) of HCC patients. Unsupervised consensus clustering was performed to categorize HCC patients into two stemness subtypes which further proved to be a predictor of tumor immune microenvironment (TIME) status, immunogenomic expressions and sensitivity to neoadjuvant therapies. Finally, four machine learning algorithms (LASSO, RF, SVM-RFE and XGboost) were applied to distinguish different stemness subtypes. Thus, a five-hub-gene based classifier was constructed in TCGA and ICGC HCC datasets to predict patients' stemness subtype in a more convenient and applicable way, and this novel stemness-based classification system could facilitate the prognostic prediction and guide clinical strategies of immunotherapy and targeted therapy in HCC.
学科与关键词
- mRNAsi-related genes can effectively distinguish hepatocellular carcinoma into new molecular subtypesWang, Canbiao; Qin, Shijie; Pan, Wanwan; Shi, Xuejia; Gao, Hanyu; Jin, Ping*; Xia, Xinyi*; Ma, Fei*Computational and Structural Biotechnology Journal, 2022, 20: 2928-2941.被引 5
- Implications of Stemness Features in 1059 Hepatocellular Carcinoma Patients from Five Cohorts: Prognosis, Treatment Response, and Identification of Potential CompoundsMai, Haoming; Xie, Haisheng; Luo, Mengqi; Hou, Jia; Chen, Jiaxuan; Hou, Jinlin*; Jiang, De-ke*Cancers, 2022, 14(3): 563.被引 8
- The Association between Immune Subgroups and Gene Modules for the Clinical, Cellular, and Molecular Characteristic of Hepatocellular CarcinomaChen, Wenbiao; Zhu, Peng; Xu, Huixuan; Hou, Xianliang; Guo, Changchun*Journal of Oncology, 2022, 2022: 7253876.
